212 related articles for article (PubMed ID: 9703859)
1. Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer.
Chiou TJ; Tung SL; Hsieh RK; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Jpn J Clin Oncol; 1998 May; 28(5):318-22. PubMed ID: 9703859
[TBL] [Abstract][Full Text] [Related]
2. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced gastric cancer with a modified regimen of etoposide/leucovorin/5-fluorouracil.
Chiou TJ; Kung SP; Hsieh RK; Fan S; Tzeng CH; Wei CH; Chen PM
Cancer Invest; 1996; 14(3):197-201. PubMed ID: 8630679
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
Cho BC; Kim JH; Kim CB; Sohn JH; Choi HJ; Lee YC; Ahn JB
Oncol Rep; 2006 Mar; 15(3):621-7. PubMed ID: 16465422
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of etoposide, leucovorin and 5-fluorouracil (ELF) in patients with advanced gastric cancer.
Au E; Koo WH; Tan EH; Ang PT
J Chemother; 1996 Aug; 8(4):300-3. PubMed ID: 8873837
[TBL] [Abstract][Full Text] [Related]
7. Etoposide, leucovorin and 5-fluorouracil in advanced gastric cancer: a phase II study.
Van Cutsem E; Filez L; Dewyspelaere J; Penninckx F; Janssens J
Anticancer Res; 1995; 15(3):1079-80. PubMed ID: 7645929
[TBL] [Abstract][Full Text] [Related]
8. Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer.
Bjarnason GA; Cripps C; Goel R; Fine S; Oza AM; Skillings JR; Kerr I; Germond CJ; Moore MJ; Maroun JA; Franssen E; Dulude H
Am J Clin Oncol; 1998 Dec; 21(6):537-42. PubMed ID: 9856651
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy comprising 5-fluorouracil, leucovorin, etoposide, and cis-diamminedichloroplatinum for the treatment of advanced gastric cancer.
Mochizuki F; Fujii M; Kasakura Y; Yamagata M; Kochi M; Wakabayashi K; Kanamori N; Takayama T
J Cancer Res Clin Oncol; 2002 Sep; 128(9):493-6. PubMed ID: 12242513
[TBL] [Abstract][Full Text] [Related]
10. Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study.
Adamo V; Scimone A; Maisano R; Altavilla G; Ferraro G; Laudani A; Pergolizzi S; Zanghì M
J Chemother; 1999 Feb; 11(1):74-7. PubMed ID: 10078785
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies.
Barone C; Corsi DC; Pozzo C; Cassano A; Fontana T; Noviello MR; Landriscina M; Colloca G; Astone A
Cancer; 1998 Apr; 82(8):1460-7. PubMed ID: 9554521
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of 5-fluorouracil, leucovorin and mitomycin C in patients with advanced gastric cancer.
Kim SR; Yuh YJ; Sohn BS; Yang SH
Tumori; 2011; 97(6):698-703. PubMed ID: 22322834
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma.
Partyka S; Dumas P; Ajani J
Cancer; 1999 Jun; 85(11):2336-9. PubMed ID: 10357402
[TBL] [Abstract][Full Text] [Related]
15. [Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer].
Lou F; Zhu YH; Pan HM
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):75-8. PubMed ID: 19538878
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced gastric cancer with etoposide, folinic acid, and fluorouracil in the clinical setting: efficacy of therapy and value of serum tumor markers.
Schulze-Bergkamen H; Zuna I; Teufel A; Stremmel W; Rudi J
Med Oncol; 2002; 19(1):43-53. PubMed ID: 12025890
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study.
Gallardo-Rincón D; Oñate-Ocaña LF; Calderillo-Ruiz G
Ann Surg Oncol; 2000; 7(1):45-50. PubMed ID: 10674448
[TBL] [Abstract][Full Text] [Related]
18. High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer--a phase II study in elderly patients or patients with cardiac risk.
Wilke H; Preusser P; Fink U; Achterrath W; Lenaz L; Stahl M; Schober C; Link H; Meyer HJ; Lucke B
Invest New Drugs; 1990 Feb; 8(1):65-70. PubMed ID: 2345071
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
Hudes GR; Lipsitz S; Grem J; Morrisey M; Weiner L; Kugler JW; Benson A
Cancer; 1999 Jan; 85(2):290-4. PubMed ID: 10023694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
